arrow
R

Rocio García-Carbonero

hospital universitario 12 de octubre
H指数:64
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Perioperative Chemotherapy and Long-Term Cure in Resected Grade 3 Gastroenteropancreatic Neuroendocrine Carcinomas: The GETNE SOUTH-NEC Study

围手术期化疗与切除后3级胃肠胰神经内分泌癌的长期治愈:GETNE SOUTH-NEC研究

2026-10-080
OAAI
Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial

静脉注射表达透明质酸酶的溶瘤腺病毒联合化疗治疗转移性胰腺癌:一项随机IIb期试验

2026-09-300
PRE
[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial

[177Lu]Lu-edotreotide与依维莫司治疗胃肠胰神经内分泌肿瘤的比较(COMPETE研究):一项III期、多中心、随机、开放标签、优效性试验

2026-07-020
PRE
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial☆

链脲佐菌素联合5-氟尿嘧啶后给予依维莫司或相反顺序用于晚期胰腺神经内分泌肿瘤患者(SEQTOR-GETNE III期研究):一项随机临床试验☆

2025-12-020
OAAI
Belzutifan for Advanced Pheochromocytoma or Paraganglioma

Jimenez C, Andreassen M, Durand A, Moog S, Hendifar A, Welin S, 等人. LITESPARK-015 研究者团队. 贝zutifan治疗晚期嗜铬细胞瘤或副神经节瘤。新英格兰医学杂志。(2025)。doi: 10.1056/NEJMoa2504964

2025-10-014
PRE
Controversies in NEN: An ENETS position statement on the treatment of patients with Grade 3 well-differentiated neuroendocrine tumours of the gastro-enteropancreatic tract

神经内分泌肿瘤(NEN)中的争议:ENETS关于胃肠胰道G3分化良好的神经内分泌肿瘤患者治疗立场声明

2025-08-090
OAAI
Fruquintinib in less pretreated patients: multivariate profile-matching analysis of FRESCO-2 to FRESCO

fruquintinib 在较少预治疗患者中的研究:FRESCO-2 与 FRESCO 的多变量配型匹配分析

2025-07-130
OA
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
2025-04-040
OAAI
Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study

西班牙晚期胃肠胰神经内分泌肿瘤患者的营养状况和生活质量:NUTRIGETNE (GETNE-S2109) 研究

2025-02-250
OA
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
2024-11-281
PRE
Exploratory biomarker evaluation of the randomized Phase 2 cohort of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer
2024-09-150
PRE
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913)
2024-08-080
OAAI
Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
2024-06-010
PRE